SFDA Kicks Off Drug Re-registration Examination And Approval
This article was originally published in PharmAsia News
Executive Summary
To ensure drug safety and eliminate low-quality and high-risk drugs, China's State FDA has officially started drug re-registration examinations and approvals. All provincial drug administrations will refer to the drug management methodology to conduct integrated checks on drug approval numbers, production techniques and prescription investigation results. Drugs will not be re-registered if their approval numbers are not genuine. In addition, SFDA demands that all provincial drug administrations set up records for drug re-registration to improve quality control and support routine supervision and on-site inspections. (Click here for more - Chinese Language)